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Abstract
Rationale Effort-related motivational symptoms such as
anergia and fatigue are common in patients with depression
and other disorders. Research implicates pro-inflammatory
cytokines in depression, and administration of cytokines can
induce effort-related motivational symptoms in humans.
Objectives The present experiments focused on the effects of
the pro-inflammatory cytokine interleukin 1-beta (IL-1β) on
effort-related choice behavior.
Methods Rats were tested on a concurrent fixed ratio 5 lever
pressing/chow feeding choice procedure, which assesses the
tendency of rats to work for a preferred food (high carbohy-
drate pellets) in the presence of a concurrently available but
less preferred substitute (laboratory chow).
Results IL-1β (1.0–4.0 μg/kg IP) shifted choice behavior,
significantly decreasing lever pressing and increasing intake
of the freely available chow. The second experiment assessed
the ability of the adenosine A2A antagonist (E)-phosphoric
acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-
dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl] propyl] es-
ter disodium salt (MSX-3) to reverse the behavioral effects of
IL-1β. MSX-3 attenuated the effort-related impairments pro-
duced by IL-1β, increasing lever pressing and also decreasing
chow intake. In the same dose range that shifted effort-related
choice behavior, IL-1β did not alter food intake or preference
in parallel free-feeding choice studies, indicating that these
low doses were not generally suppressing appetite or altering
preference for the high carbohydrate pellets. In addition, IL-
1β did not affect core body temperature.
Conclusions These results indicate that IL-1β can reduce the
tendency to work for food, even at low doses that do not
produce a general sickness, malaise, or loss of appetite. This
research has implications for the involvement of cytokines in
motivational symptoms such as anergia and fatigue.
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INTRODUCTION
Motivated behaviors can be characterized by a high degree of
behavioral activation and work output, and organisms fre-
quently make effort-related decisions based upon analyses of
motivational value and work-related response costs
(Salamone and Correa 2012; Salamone et al. 2002). Effort-
based choice behavior is studied using tasks that offer choices
between high effort options leading to highly valued rein-
forcers vs. low effort/low reward options (Salamone et al.
2007, 2012). Exertion of effort in motivated behavior and
effort-related choice behavior are regulated by neural circuits
involving nucleus accumbens dopamine (DA), prefrontal/
anterior cingulate cortex, ventral pallidum, and basolateral
amygdala (Salamone et al. 1997, 2007; Walton et al. 2003;
E. J. Nunes : P. A. Randall :A. Estrada :B. Epling : E. E. Hart :
C. A. Lee :M. Correa : J. D. Salamone (*)
Department of Psychology, University of Connecticut, Storrs,
CT 06269-1020, USA
e-mail: john.salamone@uconn.edu
Y. Baqi : C. E. Müller
Pharma-Zentrum Bonn, Pharmazeutisches Institut, Pharmazeutische
Chemie, Universität Bonn, Bonn, Germany
M. Correa




Cagniard et al. 2006; Floresco and Ghods-Sharifi 2007;
Mingote et al. 2008a; Font et al. 2008; Farrar et al. 2008,
2010; Hauber and Sommer 2009; Mai et al. 2012; Salamone
and Correa 2012). It has been suggested that tasks measuring
effort-related choice behavior could be used as animal models
of motivational symptoms such as anergia and fatigue, which
are seen in patients with major depression and other condi-
tions (Salamone et al. 2006, 2007, 2012; Salamone and Correa
2012; Dantzer et al. 2012). This suggestion is consistent with
recent human studies showing that decreased selection of high
effort/high reward options is seen in patients with major
depression (Treadway et al. 2012) and also in schizophrenics
manifesting a high degree of negative symptoms (Gold et al.
2013), whereas the opposite effect is produced by administra-
tion of amphetamine (Wardle et al. 2011).
Cytokines are known to play a critical role in the regulation
of the immune system, which coordinates physiological re-
sponses to infection, injury, and foreign antigens (Dantzer
2001). Evidence gathered over the last few decades has dem-
onstrated that pro-inflammatory cytokines play a role in as-
pects of depression, including motivational symptoms, such
as psychomotor slowing, anergia, and fatigue (Bret-Dibat
et al. 1995; Dantzer 2001; Raison et al. 2006; Felger and
Miller 2012; Dantzer et al. 2012). Depressed patients have
elevated levels of pro-inflammatory cytokines, such as tumor
necrosis factor alpha, interleukin 6 (IL-6), and interleukin 1β
(IL-1β) as compared with the general population (Dowlati
et al. 2010; Hiles et al. 2012), and high levels of IL-1β in
depressed patients were predictive of a lack of therapeutic
response to the antidepressants nortriptyline and escitalopram
(Cattaneo et al. 2013). In addition, patients with cancer or viral
infections are often treated with these cytokines, and side
effects of this treatment can involve depressive-like symp-
toms, including fatigue/anergia (Capuron et al. 2002, 2009;
Felger et al. 2012a). In fact, fatigue and loss of energy are
reported to be the most common symptoms induced by inter-
feron alpha (IFN-α; these symptoms occur in 80% of patients
receiving treatment with IFN-α (Miller 2009; Felger et al.
2012a). Moreover, patients that received IFN-α treatment,
when compared with medically healthy people with major
depression, showed less agitation and suicidal ideation, but
significantly greater psychomotor slowing (Capuron et al.
2009). Pro-inflammatory cytokines are thought to influence
brain function inmultiple ways, and there is evidence that they
act on macrophage-like cells in the choroid plexus and
circumventricular organs that induce the central synthesis of
cytokines, which in turn diffuse into the brain tissue (Dantzer
2009). In addition, peripheral cytokines can act on afferent
branches of cranial nerves such as the glossopharyngeal and
vagus, instigating the central production of cytokines by mi-
croglia (Dantzer 2009). Centrally acting cytokines affect
transmission of brain monoamine systems, including DA,
norepinephrine, and serotonin, all of which have been
implicated in depression (Song et al. 2008; Miller 2009;
Dantzer 2009). Recent evidence suggests that mesolimbic
DA may be particularly sensitive to inflammatory cytokines,
where they have been reported to interfere with vesicular DA
storage and DA synthesis (Felger and Miller 2012).
In rats and mice, administration of IL-1β produced
depressive-like effects in commonly used tasks such as the
forced swim and tail suspension tests (Minor et al. 2003; Dunn
and Swiergiel 2005; Hanff et al. 2010) and also reduced social
exploration and locomotor activity (Castanon et al. 2001).
Lipopolysaccaride, a component of the outer membrane of
gram-negative bacteria, increased the expression of inflam-
matory cytokines and induced depressive-like effects in mice
tested on the tail suspension and forced swim tests (Frenois
et al. 2007; O'Connor et al. 2009), and intracranial adminis-
tration of IL-6 to rats produced depressive-like effects in the
forced swim test (Wu and Lin 2008). In addition, some studies
indicate that administration of cytokines to rodents can affect
behavioral activation and exertion of effort in rats responding
on instrumental tasks. Injection of the cytokine inducer
polyriboinosinic/polyribocytidylic acid decreased spontane-
ous wheeling in rats (Katafuchi et al. 2005). Furthermore,
Merali et al. (2003) reported that administration of IL-1β to
rats reduced lever pressing on a progressive ratio schedule.
The present experiments characterized the ability of the
pro-inflammatory cytokine IL-1β to alter effort-related choice
behavior as assessed by the concurrent fixed ratio 5 (FR5)/
chow-feeding procedure (Salamone et al. 1991, 2007). This
task assesses the tendency of rats to work for a preferred food
(high carbohydrate pellets) in the presence of a concurrently
available but less preferred substitute (laboratory chow). Thus,
rats can either lever press on a FR5 schedule of reinforcement
for a more preferred food (high carbohydrate pellets) or ap-
proach and consume the less preferred laboratory chow that is
freely available in the operant chamber. Rats trained on this
procedure receive most of their food by responding on the
lever for the more preferred sucrose pellet and eat very little of
the freely available chow. Previous research has shown that
this task is sensitive to the effects of various pharmacological
manipulations, including low doses of DA antagonists and
accumbens DA depletions or antagonism (Salamone et al.
1991, 2002, 2007, 2009; Farrar et al. 2010), stimulation of
accumbens core adenosine A2A receptors (Font et al. 2008), or
stimulation of GABAA receptors in ventral pallidum (Farrar
et al. 2008), all of which shift choice behavior by decreasing
lever pressing and increasing chow intake. This shift in choice
behavior is not dependent upon changes in food consumption
or preference and is not mimicked by pre-feeding or appetite
suppressant drugs, which fail to increase chow intake at doses
that suppress lever pressing (Salamone et al. 1991, 2002;
Cousins et al. 1994; Koch et al. 2000; Sink et al. 2008;
Nunes et al. 2013). In the present study, experiment 1 exam-
ined the ability of the pro-inflammatory cytokine IL-1β to
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produce effort-related impairments in rats tested on the con-
current FR5/chow-feeding procedure, and it was hypothesized
that IL-1β would decrease lever pressing but increase intake
of the concurrently available lab chow. Experiment 2 studied
the ability of the adenosine A2A antagonist (E)-phosphoric
acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-
dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl] propyl] es-
ter disodium salt (MSX-3) to reverse the effort-related effects
of IL-1β. MSX-3 was studied because of research showing
that adenosine A2A antagonists can attenuate the effort-related
effects of DA antagonists (Farrar et al. 2007; Nunes et al.
2010; Santerre et al. 2012) and can produce effects that are
consistent with the behavioral profile of an antidepressant in
rodents tested on the swim test or tail suspension task (El
Yacoubi et al. 2003; Hodgson et al. 2009; Hanff et al. 2010).
Finally, control experiments assessed the effects of IL-1β on
food intake and preference and on core body temperature.
Materials and methods
Subjects
Adult male, drug-naïve, Sprague Dawley rats (Harlan Sprague
Dawley, Indianapolis, IN, USA) were house in a colony
maintained at 23 °C with 12-h light/dark cycles (lights on at
7:00 hours). Rats (n =32) weighed 290–340 g at the beginning
of the study and were initially food restricted to 85 % of their
free-feeding body weight for operant training. Rats were fed
supplemental chow to maintain weight throughout the study,
with water available ad libitum. Despite the food restriction,
rats were allowed modest weight gain throughout the experi-
ment. Different groups of rats were used for each experiment.
Animal protocols were approved by the University of Con-
necticut animal care and use committee, and followed NIH
guidelines.
Pharmacological agents and selection of doses:
Recombinant rat IL-1β was obtained from R&D systems
(Minneapolis, MN, USA) and was dissolved in 0.9 % saline
that also served as the vehicle control. The doses of IL-1β
were based on previously published data (Merali et al. 2003)
and on extensive pilot studies conducted to determine the time
intervals and the precise dose range to be used (pilot studies
showed that higher doses of IL-1β, such as 8.0-10.0 μg/kg,
suppressed both lever pressing and food intake). MSX-3 was
provided by Christa Müller at the Pharmazeutisches Institut,
Universität Bonn, in Bonn, Germany (Hockemeyer et al.
2004). To prepare the drug solution, MSX-3 (free acid) was
dissolved in 0.9 % saline, and pH was adjusted by titrating
with microliter quantities of 1.0 N NaOH until the solid drug
was in solution. The final pHwas usually 7.5±0.2 and was not
allowed to exceed 7.8.
Behavioral procedures:
Behavioral sessions were conducted in operant conditioning
chambers (28×23×23 cm; Med Associates). Rats were ini-
tially trained to lever press on a continuous reinforcement
schedule (30-min sessions, during 5 days) to obtain 45-mg
pellets (Bioserve, Frenchtown, NJ, USA), and were then
shifted to the FR5 schedule (30-min sessions, 5 days/week)
and trained for several additional weeks. Rats were then
trained on the concurrent FR5/chow-feeding procedure. With
this task weighed amounts of laboratory chow (typically 15–
20 g, three large pieces; labortory diet, 5P00 Prolab RHM
3000, Purina Mills, St. Louis MO, USA) were concurrently
available on the floor of the chamber during the FR5 sessions.
At the end of the session, rats were immediately removed from
the chambers, and food intake was determined by weighing
the remaining food (including spillage). Rats were trained
until they attained stable levels of baseline lever pressing
and chow intake (i.e., consistent responding over 1,200 lever
presses/30 min), after which drug testing began. For most
baseline days, rats did not receive supplemental feeding;
however, over weekends and after drug tests, rats usually
received supplemental chow in the home cage. On baseline
and drug treatment days, rats normally consumed all the
operant pellets that were delivered from lever pressing during
each session. For the food preference study, rats were trained
for several weeks in 30-min sessions in which both Bio-serv
pellets and laboratory chow were concurrently and freely
available for consumption. At the end of the session, rats were
immediately removed from the chambers, and food intake was
determined by weighing both of the remaining foods (includ-
ing spillage).
Experimental procedures
Rats were trained on the concurrent FR5/chow-feeding pro-
cedure (as described above) before testing began, and each
experiment employed different groups of rats. Experiments 1–
4 used a within-groups design; with each rat receiving all
intraperitoneal (IP) drug treatments in their particular experi-
ment in a randomly varied order (one treatment per week, with
none of the treatment sequences repeated across different
animals in the same experiment). Baseline (i.e., nondrug)
sessions were conducted four additional days per week. Be-
havioral measures included both the number of lever presses
and the amount of freely available lab chow that was con-
sumed. The specific treatments and testing times for each
experiment are listed below.
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Experiment 1: effects of systemic administration of IL-1β
on the concurrent FR5/chow-feeding procedure
All animals were trained until stable baseline performance
was achieved (i.e., lever presses consistently over 1,200/ses-
sion). On drug test days, all animals (n =8) received IP injec-
tions of the following doses of IL-1β/saline vehicle, 1.0, 2.0,
and 4.0 μg/kg. This experiment used a within-groups design,
with all rats receiving all drug treatments in a randomly varied
order. Baseline training (i.e., nondrug) sessions were
conducted four additional days per week, and behavioral
performance on these baseline days was unaffected by the
previous injections. All injections were given 90 min before
the beginning of the testing session.
Experiment 2: effects of systemic administration of IL-1β
on the concurrent FR5/chow-feeding procedure: reversal
with MSX-3
All animals were trained until a stable baseline performance
was achieved (i.e., lever presses over 1,200). On drug test
days, rats (n =8) received IP injections of the following doses
of IL-1β plus MSX-3/saline vehicle plus saline vehicle,
4.0 μg/kg IL-1β plus saline vehicle, 4.0 μg/kg IL-1β plus
0.5 mg/kg MSX-3, 4.0 μg/kg IL-1β plus 1.0 mg/kg MSX-3,
and 4.0 μg/kg IL-1β plus 2.0 mg/kg MSX-3. IL-1β injections
were given 90 min before testing, and MSX-3 was injected
20 min before testing. Experiment 2 used a within-group
design, with all rats receiving all drug treatments in a random-
ly varied order. Baseline training (i.e., nondrug) sessions were
conducted four additional days per week.
Experiment 3: effects of systemic administration of IL-1β
on food intake and preference
Rats were extensively trained until stable baseline perfor-
mance was achieved (i.e., food consumption over 10 g). Then,
the rats (n =8) received IP injections of the following doses of
IL-1β/saline vehicle, 1.0, 2.0, and 4.0 μg/kg. This experiment
used a within-group design, with all rats receiving all drug
treatments in a randomly varied order. Baseline training (i.e.,
nondrug) sessions were conducted four additional days per
week. All injections were given 90 min before the beginning
of the testing session.
Experiment 4: effects of IL-1β on body temperature
Untrained rats (n =8) received the following injections in a
randomly varied order once per week: vehicle saline or
4.0 μg/kg IL-1β IP, 105 min before testing (i.e., at a time that
corresponded to the midpoint of the operant behavior tests).
This experiment used a within-group design, with all rats
ultimately receiving both treatments. Rats were held loosely
by an experimenter, while a thin, flexible thermistor probe
(Fisher Scientific, Pittsburgh, PA) was then inserted 6 cm into
the animal's rectum. Temperature was recorded when it ceased
to fluctuate for at least 5 s. These methods have previously
been used to measure temperature changes induced by canna-
binoid receptor agonists (McLaughlin et al. 2005, 2013).
Statistical analyses
Number of lever presses and gram quantity of chow intake
from the 30-min sessions in experiments 1–3 were analyzed
with repeated measures of analysis of variance (ANOVA).
When the overall ANOVA was significant, non-orthogonal
planned comparisons using the overall error term was used
to compare each treatment with the vehicle control group
(Keppel 1991). For these comparisons, α level was kept at
0.05 because the number of comparisons was restricted to the
number of treatments minus one (Keppel 1991). With this
analysis, each condition that combined IL-1β plus MSX-3
was compared with the IL-1β plus vehicle condition.
Results
Experiment 1: effects of systemic administration of IL-1β
on the concurrent FR5/chow-feeding procedure
Systemic administration of IL-1β significantly decreased le-
ver pressing and produced a concurrent increase in the con-
sumption of the freely available lab chow as shown in Fig. 1a,
b. The ANOVA revealed a significant effect of dose on lever
pressing F (3, 21)=31.5; p <0.05. There was also an overall
significant effect of dose on chow intake F(3, 21)=11.3; p <
0.05. Planned comparisons were performed and showed that
the two highest doses of IL-1β significantly decreased lever
pressing and increased the consumption of the freely available
lab chow relative to control (p <0.05).
Experiment 2: effects of systemic administration of IL-1β
on the concurrent FR5/chow-feeding procedure: reversal
with MSX-3
The results of experiment 2 are shown in Fig. 2a, b. MSX-3
was able to attenuate the behavioral effects of IL-1β. There
was an overall significant effect of drug treatment on lever
pressing F (4, 28)=22.2; p <0.05). There was also an overall
significant effect of drug treatment on chow intake F(4, 28)=
6.7; p <0.05). Planned comparisons were performed and
showed that IL-β suppressed lever pressing and increased
chow intake, and that the two highest doses of MSX-3 were
able to attenuate the effects of IL-Iβ, both on lever pressing
and consumption of the freely available lab chow, relative to
the IL-1β alone condition (p <0.05).
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Experiments 3–4: IL-1β had no effect on food intake, food
preference, or body temperature
The results of the feeding study (experiment 3) are shown in
Fig. 3. Administration of IL-1β had no effect on food intake,
or preference of the high carbohydrate pellets vs. laboratory
chow. There was a significant difference between food type
consumed, with rats preferring the Bio-serv pellets over the
standard lab chow (F (1, 14)=958.2; p <0.001). However,
there was no significant effect of drug treatment on food
intake (p >0.05), and no significant drug treatment×food type
interaction (p >0.05). In experiment 4, injections of IL-1β had
no effect on core body temperature. Mean (±SEM) body
temperatures (in degrees Celsius) for each condition were as
follows: saline vehicle, 38.19±0.16; IL-1β, 37.91±0.22 (t =
1.01, df =7, n.s.).
Discussion
These experiments were conducted to characterize the behav-
ioral effects of the pro-inflammatory cytokine IL-1β using the
concurrent FR5/chow-feeding procedure (Salamone et al.
1991, 2009; Nunes et al. 2010). Administration of IL-1β
shifted effort-related choice behavior as measured by the
FR5/chow-feeding choice task, decreasing lever pressing
while producing a concomitant increase in the consumption
of the concurrently available lab chow. Thus, like DA antag-
onism (Salamone et al. 1991, 2001; Sink et al. 2008), systemic
and intra-accumbens injections of the DA-depleting agent
tetrabenazine (Nunes et al., unpublished data), and intra-
accumbens injections of pilocarpine (Nunes et al. 2013), IL-
a
b
Fig. 1 The effects of IL-1β on FR5/chow-feeding choice performance. a
Mean (±SEM) number of lever presses after treatment with vehicle and
various doses of IL-1β (1.0–4.0 μg/kg IP). b Mean (±SEM) intake of lab
chow (in grams) after treatment with vehicle and various doses of IL-1β.
*p <0.05, different from vehicle, planned comparison
a
b
Fig. 2 The effects of the adenosine A2A antagonist MSX-3 on IL-1β-
induced changes in the performance of the FR5/chow-feeding choice
task. Rats received IP injections of vehicle plus vehicle (Veh/Veh ),
4.0 μg/kg IL-1β plus vehicle (IL-1β/Veh), and 4.0 μg/kg IL-1β plus
0.5, 1.0, or 2.0 mg/kg doses of MSX-3 (in molars). a Mean (±SEM)
number of lever presses during the 30-min session. b Mean (±SEM) gram
quantity of chow intake. #p <0.05, IL-1β plus vehicle significantly
different from vehicle/vehicle; *p <0.05, MSX-3 plus IL-1β significantly
different from IL-1β plus vehicle
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1β can suppress food-reinforced lever pressing at doses that
leave behavior directed towards the acquisition and consump-
tion of food. These results are consistent with other data
suggesting that IL-1β can affect instrumental responding
reinforced by food. Larson et al. (2002) showed that admin-
istration of IL-1β reduced lever pressing on progressive ratio
and FR32 schedules of reinforcement in mice, but had little
effect on FR4 responding. Furthermore, in rats tested on a
progressive ratio schedule, IL-1β decreased lever pressing
and lowered the highest ratio achieved (Merali et al. 2003).
To produce a drug-induced shift in effort-related choice
behavior, functions such as primary food motivation, appetite,
and the ability to consume food must be relatively intact. This
could have been problematic with injections of IL-1β, be-
cause cytokines produce behavioral effects that are collective-
ly referred to as “sickness behavior,” which include decreased
motor activity and loss of appetite, as well as psychomotor
slowing and fatigue (Kent et al. 1992; Aubert et al. 1997;
Harden et al. 2008; Dantzer 2009; Dantzer et al. 2012; Raedler
2011; Dellagioia et al. 2013; Felger and Miller 2012). Thus, it
could have been difficult to disentangle effects of IL-1β on
food-reinforced lever pressing vs. those on food intake, since
other drugs that suppress appetite or induce aversive food
reactions, including amphetamine, fenfluramine, and canna-
binoid CB1 antagonists/inverse agonists, all fail to increase
chow intake at doses that suppress food-reinforced lever
pressing (Cousins et al. 1994; Salamone et al. 2002; Sink
et al. 2008). In addition, drugs that produce substantial
drowsiness/sedation (e.g., the adenosine A2A agonist CGS
21680) have been shown to decrease both lever pressing and
chow intake (Mingote et al. 2008b), and did not induce the
shift from lever pressing to chow intake at systemic doses that
induced sedation (Font et al. 2008). Our own pilot studies
indicated that higher doses of IL-1β could suppress food
intake in addition to lever pressing, but the low doses used
in experiments 1 above enabled us to observe a shift in choice
from lever pressing to chow intake. Moreover, in the dose
range tested, IL-1β did not affect intake of Bio-serv pellets or
the preference for pellets over chow in free-feeding preference
tests (experiment 3). Furthermore, although some studies have
shown that IL-1β can increase body temperature 2–4 h after
IP injection (McLaughlin et al. 1992; Mouihate et al. 1998;
Taylor et al. 2002), the results of experiment 4 demonstrated
that IL-1β did not significantly affect body temperature at
105min after injection (i.e., a time period corresponding to the
midpoint of the operant behavior session). Taken together,
these results suggest that IL-1β was not suppressing lever
pressing for Bio-serv pellets because of changes in appetite,
food preference, or a general sickness or malaise that was
strong enough to reduce primary food motivation. Instead,
the present results indicate that under the specific conditions
studied in the present experiments, rats treated with IL-1β
were still directed towards the acquisition and consumption of
food, but were less likely to work for food by lever pressing.
Although the mechanism of action through which IL-1β
can affect performance on the FR5/chow-feeding choice task
is unknown, pro-inflammatory cytokines are reported to re-
duce DA transmission (Kamata et al. 2000; Shuto et al. 1997;
Felger et al. 2012b; Capuron et al. 2012; Felger and Miller
2012; but see also Song et al. 2007). Thus, in view of the
literature implicating DA in effort-related choice behavior, it is
possible that DAergic mechanisms may contribute to the
effort-related effects of IL-1β. Recent studies indicate that
cytokines can interfere with DA storage by reducing expres-
sion of the type 2 monoamine transporter (VMAT2) and also
can suppress DA synthesis by reducing the availability of the
essential cofactor tetrahydrobiopterin (Felger and Miller
2012). Patients treated with pro-inflammatory cytokines de-
velop psychomotor slowing and fatigue and show reduced
activation of nucleus accumbens as measured by fMRI
(Capuron et al. 2012). Moreover, reductions in the presence
of the DA metabolite homovanillic acid in cerebrospinal fluid
were correlated with the degree of fatigue in patients treated
with IFN-α (Felger and Miller 2012). These results suggest
that cytokines may exert effects on DA that cause animals to
reallocate their instrumental response selection based upon the
response requirements of the task and select lower cost alter-
natives to obtain food (Salamone et al. 2007, 2009). Further-
more, as described above, the effects of IL-1β in rats
responding on the FR5/chow-feeding choice procedure re-
sembled those produced by DA antagonism or depletion
(Salamone et al. 2007; Salamone and Correa 2012). Future
research using microdialysis or measures of DA-related signal
transduction (Segovia et al. 2011, 2012; Santerre et al. 2012;
Randall et al. 2012) should be used to study the effects of IL-
1β on DA transmission, and other transmitters also should be
investigated.
Fig. 3 This figure shows the results of experiment 3, which assessed the
effects of IL-1β on food intake and preference. Mean (±SEM) intake of
Bio-serv pellets and lab chow (in grams) after treatment with vehicle and
various doses (1.0–4.0 μg/kg IP) of IL-1β. There was an overall signif-
icant preference for Bio-serv pellets over chow, but no drug effects and no
drug treatment by food type interaction
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Experiment 2 studied the ability of the selective adenosine
A2A antagonist MSX-3 to reverse the effects of IL-1β on the
concurrent FR5/chow choice task. Though previous work has
shown that MSX-3 had no effect of FR5/chow-feeding choice
performance when administered on its own (Farrar et al.
2007), co-administration of MSX-3 significantly reversed
the behavioral effects of IL-1β injections, restoring the base-
line behavioral pattern by increasing lever pressing and de-
creasing chow intake in IL-1β-treated rats. These results are
consistent with previous research demonstrating that adeno-
sine A2A receptor blockade or genetic deletion can reverse the
effort-related effects of DA antagonism and depletion (Farrar
et al. 2007, 2010; Worden et al. 2009; Mott et al. 2009;
Salamone et al. 2009; Nunes et al. 2010; Pardo et al. 2012).
Furthermore, the present findings are consistent with reports
showing that the adenosine A2A antagonists can produce
effects that are consistent with the behavioral profile of an
antidepressant in rodents tested on the swim test or tail sus-
pension task (El Yacoubi et al. 2003; Hodgson et al. 2009;
Hanff et al. 2010). The precise mechanism through which
adenosine A2A antagonists exert their motivational effects is
unknown, although anatomical and neurochemical evidence
would indicate that a likely substrate is the enkephalin-
positive medium spiny neurons in nucleus accumbens (Ferré
et al. 1997; Rosin et al. 1998). In striatal regions, adenosine
A2A receptors and DA D2 receptors are concentrated on
enkephalin-positive GABAergic ventral striatopallidal neu-
rons (Ferré et al. 1997, 2008; Rosin et al. 1998; Mingote
et al. 2008a, b), and adenosine A2A receptor antagonism has
been shown to reverse the basic cellular effects of DA deple-
tion or D2 antagonism on these neurons (Farrar et al. 2010;
Santerre et al. 2012; Nunes et al., unpublished data). It has
been suggested that adenosine A2A receptor blockade could be
useful in treating motivational symptoms in humans such as
psychomotor slowing, anergia, apathy, and fatigue, which are
evident in major depression and other disorders (Salamone
et al. 2009, 2012; Farrar et al. 2007, 2010; Nunes et al. 2010;
Santerre et al. 2012). Thus, it is possible that adenosine A2A
receptor antagonists could also be useful for treating effort-
related motivational symptoms produced by administration of
cytokines.
In summary, these experiments focused on the behavioral
effects of systemic administration of the pro-inflammatory
cytokine IL-1β. IL-1β shifted effort-related choice, producing
a significant decrease in lever pressing with a concurrent
increase in the consumption of the freely available lab chow.
The adenosine A2A antagonist MSX-3 attenuated the behav-
ioral impairments produced by systemic administration of IL-
1β. In the same dose range that shifted effort-related choice
behavior, IL-1β did not alter food intake or preference in
parallel free-feeding choice studies, indicating that these low
doses were not generally suppressing appetite or altering
preference for the high carbohydrate pellets. In addition, IL-
1β did not affect core body temperature. These results indicate
that IL-1β can reduce the tendency to work for food, even at
low doses that do not produce a general food-related malaise
or a loss of appetite. This research has implications for the
involvement of cytokines in motivational symptoms such as
anergia and fatigue in depressed patients, as well as those
receiving cytokine treatment (Dantzer et al. 2012). Cytokines
also are thought to be involved in the anergia/fatigue-related
symptoms seen in patients with infectious or inflammatory
disease (Dantzer et al. 2008; Miller 2009; Harboe et al. 2009),
multiple sclerosis (Lapierre and Hum 2007), and Parkinson's
disease (Katsarou et al. 2007). Thus, it should be recognized
that tests of effort-related choice behavior are not intended to
serve as animal models of depression, per se. Rather, they are
being studied as potential models of a specific class of symp-
toms (i.e., effort-related motivational symptoms) that is char-
acteristic of depression, but also spans multiple disorders and
conditions (Treadway et al. 2012; Dantzer et al. 2012; Gold
et al. 2013). This suggestion is consistent with the recent trend
in mental health research that places less emphasis on tradi-
tional diagnostic categories, and instead focuses on the neural
circuits mediating specific pathological symptoms (i.e., the
Research Domain Criteria approach; Cuthbert and Insel
2013).
Acknowledgments This work was supported by a grant to J.S. from the
National Institute of Mental Health (MH094966), and to Merce Correa
from Fundació Bancaixa/U. Jaume I. (P1.1B2010-43), and a SURF grant
to B. Epling.
Disclosure/conflict of interest J. Salamone has received grants from
Merck-Serrono, Pfizer, and Roche and is a consultant for Merz.
References
Aubert A, Kelley KW, Dantzer R (1997) Differential effect of lipopoly-
saccharide on food hoarding behavior and food consumption in rats.
Brain Behav Immun 11(3):229–238
Bret-Dibat JL, Bluthé RM, Kent S, Kelley KW, Dantzer R (1995)
Lipopolysaccharide and interleukin-1 depress food motivated be-
havior in mice by a vagal-mediated mechanism. Brain Behav
Immun 9(3):242–246
Cagniard B, Balsam PD, Brunner D, Zhuang X (2006) Mice with chron-
ically elevated dopamine exhibit enhanced motivation, but not
learning, for a food reward. Neuropsychopharmacology 31:1362–
1370
Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ (2002)
Treatment of cytokine-induced depression. Brain Behav Immun
16(5):575–580
Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH
(2009) Does cytokine-induced depression differ from idiopathic
major depression in medically healthy individuals? J Affect Disord
119:181–185
Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ,
Votaw JR, Goodman MM, Miller AH (2012) Dopaminergic mech-
anisms of reduced basal ganglia responses to hedonic reward during
Psychopharmacology (2014) 231:727–736 733
interferon alpha administration. Arch Gen Psychiatry 69(10):1044–
1053
Castanon N, Bluthé RM, Danzter R (2001) Chronic treatment with the
atypical antidepressant tianeptine attenuates sickness behavior in-
duced by peripheral but not central lipopolysaccharide and
interleukin-1beta in the rat. Psychopharmacology (Berl) 154(1):
50–60
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ,
Craig IW, Anacker C, Zunsztain PA,McGuffin P, Pariante CM (2013)
Candidate genes expression profile associated with antidepressants
response in the GENDEP Study: differentiating between baseline
‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology
38:377–385
Cousins MS, Wei W, Salamone JD (1994) Pharmacological characteriza-
tion of performance on a concurrent lever pressing/feeding choice
procedure: effects of dopamine antagonists, cholinomimetic, sedative
and stimulant drugs. Psychopharmacology (Berl) 116(4):529–537
Cuthbert BN, Insel TR (2013) Toward the future of psychiatric diagnosis:
the seven pillars of RDoC. BMC Med 11:126
Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and
implications. Ann N YAcad Sci 933:222–234
Dantzer R, O’Connor JC, Freund GC, Johnson RW, Kelley KW (2008)
From inflammation to sickness and depression: when the immune
system subjugates the brain. Nat Rev Neurosci 9:46–57
Dantzer R (2009) Cytokine, sickness behavior, and depression. Immunol
Allergy Clin North Am 29:247–264
Dantzer R, Meagher MW, Cleeland CS (2012) Translational approaches
to treatment-induced symptoms in cancer patients. Nat Rev Clin
Oncol 9:414–426
Dellagioia N, Devine L, Pittman B, Hannestad J (2013) Bupropion pre-
treatment of endotoxin-induced depressive symptoms. Brain Behav
Immun 31:197–204
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK,
Lanctôt KL (2010) A meta-analysis of cytokines in major depres-
sion. Biol Psychiatry 67(5):446–457
Dunn AJ, Swiergiel AH (2005) Effects of interleukin-1 and endotoxin in
the forced swim and tail suspension tests in mice. Pharmacol
Biochem Behav 81(3):688–693
El Yacoubi M, Costentin J, Vaugeois JM (2003) Adenosine A2A recep-
tors and depression. Neurology 61(Suppl 6):S82–S87
Farrar AM, Pereira M, Velasco F, Hockemeyer J, Muller CE, Salamone
JD (2007) Adenosine A(2A) receptor antagonism reverses the ef-
fects of dopamine receptor antagonism on instrumental output and
effort-related choice in the rat: implications for studies of psycho-
motor slowing. Psychopharmacology (Berl) 191:579–586
Farrar AM, Font L, Pereira M, Mingote S, Bunce JG, Chrobak JJ,
Salamone JD (2008) Forebrain circuitry involved in effort-related
choice: injections of the GABAA agonist muscimol into ventral
pallidum alter response allocation in food-seeking behavior. Neuro-
science 152:321–330
Farrar AM, Segovia KN, Randall PA, Nunes EJ, Collins LE, Stopper CM,
Port RG, Hockemeyer J, Müller CE, CorreaM, Salamone JD (2010)
Nucleus accumbens and effort-related functions: behavioral and
neural markers of the interactions between adenosine A2A and
dopamine D2 receptors. Neuroscience 166:1056–1067
Felger JC, Miller AH (2012) Cytokine effects on the basal ganglia and
dopamine function: the subcortical source of inflammatory malaise.
Front Neuroendocrinol 33(3):315–327
Felger JC, Cole SW, Pace TW, Hu F, Woolwine BJ, Doho GH, Raison
CL, Miller AH (2012a) Molecular signatures of peripheral blood
mononuclear cells during chronic interferon-α treatment: relation-
ship with depression and fatigue. Psychol Med 42:1591–1603
Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL,
Miller AH (2012b) Tyrosine metabolism during interferon-alpha
administration: association with fatigue and CSF dopamine concen-
trations. Brain Behav Immun 31:153–160
Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-
dopamine receptor-receptor interactions as an integrative mecha-
nism in the basal ganglia. Trends Neurosci 20:482–487
Ferré S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, Lluis C,
Franco R, Azdad K, Schiffmann SN (2008) An update on adenosine
A2A-dopamine D2 receptor interactions: Implications for the func-
tion of G-protein coupled receptors. Curr Pharm Des 14:1468–1474
Floresco SB, Ghods-Sharifi S (2007) Amygdala-prefrontal contrical cir-
cuitry regulates effort-based decision making. Cereb Cortex 17(2):
251–260
Font L,Mingote S, Farrar AM, PereiraM,Worden L, Stopper C, Port RG,
Salamone JD (2008) Intra-accumbens injections of the adenosine
A2A agonist CGS 21680 affect effort-related choice behavior in
rats. Psychopharmacology (Berl) 199:515–526
Frenois F, Moreau M, O'Connor J, Lawson M, Micon C, Lestage J,
Kelley KW, Dantzer R, Castanon N (2007) Liopolysaccharide in-
duces delayed FosB/DeltaFosB immunostaining within the mouse
extended amygdala, hippocampus and hypothalamus, that parallel
t h e e x p r e s s i o n o f d e p r e s s i v e - l i k e b e h a v i o r .
Psychoneuroendocrinology 32:516–531
Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ
(2013) Negative symptoms of schizophrenia are associated with
abnormal effort-cost computations. Biol Psychiatry 74:130–136
Hanff TC, Furst SJ, Minor TR (2010) Biochemical and anatomical
substrates of depression and sickness behavior. Isr J Psychiat Rel
Sci 47:64–71
Harboe E, Tjensvoll AB, Vefring HK, Goransson LG, Kvaloy JT, Omdal
R (2009) Fatigue in primary Sjogren's syndrome—a link to sickness
behaviour in animals? Brain Behav Immun 23:1103–1108
Harden LM, du Plessis I, Poole S, Laburn HP (2008) Interleukin (IL)-6
and IL-1 beta act synergistically within the brain to induce sickness
behavior and fever in rats. Brain Behav Immun 22(6):838–849
Hauber W, Sommer S (2009) Prefrontostriatal circuitry regulates effort-
related decision making. Cereb Cortex 19(10):2240–2247
Hiles SA, Baker AL, de Malmanche T, Attia J (2012) A meta-analysis of
difference in IL-6 and IL-10 between people with and without
depression: exploring the causes of heterogeneity. Brain Behav
Immun 26(7):1180–1188
Hockemeyer J, Burbiel JC, Müller CE (2004)Multigram-scale syntheses,
stability, and photoreactions of A2A adenosine receptor antagonists
with 8-styrylxanthine structure: potential drugs for Parkinson's dis-
ease. J Org Chem 69:3308–3318
Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A,
Fredduzzi S, Cohen-Williams ME, Higgins GA, Impagnatiello F,
Nicolussi E, Parra LE, Foster C, Zhai Y, Neustadt BR, Stamford
AW, Parker EM, Reggiani A, Hunter JC (2009) Characterization of
the potent and highly selective A2A receptor antagonists
preladenant and SCH 412348 [7-[2-[4–2,4-difluorophenyl]-1
piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e ][1,2,
4]triazolo[1,5-c]pyrimidin-5-amine]in rodent models of movement
disorders and depression. J Pharmacol Exp Ther 330:294–303
Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T (2000)
Effect of single intracerebroventricular injection of alpha-interferon
on monoamine concentra t ions in the ra t bra in . Eur
Neuropsychopharmacol 10(2):129–132
Katafuchi T, Kondo T, Take S, Yoshimura M (2005) Enhanced expres-
sion of brain interferon-alpha and serotonin transporter in immuno-
logically induced fatigue in rats. Eur J Neurosci 22:2817–2826
Katsarou Z, Bostantjopoulou S, Hatzizisi O, Giza E, Soler-Cardona A,
Kyriazis G (2007) Immune factors or depression? Fatigue correlates
in Parkinson's disease. Rev Neurol 45:725–728
Kent S, Bluthé RM, Kelley KW, Dantzer R (1992) Sickness behavior as
a new target for drug development. Trends Pharmacol Sci 13:24–
28
Keppel G (1991) Design and analysis: a researcher's handbook, 3rd edn.
Prentice-Hall, Englewood Cliffs, NJ
734 Psychopharmacology (2014) 231:727–736
Koch M, Schmid A, Schnitzler HU (2000) Role of nucleus accumbens
(DA) D1 and D2 receptors in instrumental and Pavlovian paradigms
of conditioned reward. Psychopharmacology (Berl) 152:67–73
Lapierre Y, Hum S (2007) Treating fatigue. Internat MS J 14:64–71
Larson SJ, Romanoff RL, Dunn AJ, Glowa JR (2002) Effects of
interleukin-1beta on food-maintained behavior in the mouse. Brain
Behav Immun 16(4):398–410
Mai B, Sommer S, HauberW (2012)Motivational states influence effort-
based decision making in rats: the role of dopamine in the nucleus
accumbens. Cogn Affect Behav Neurosci 12:74–84
McLaughlin CL, Rogan GJ, Tou J, Baile CA, JoyWD (1992) Food intake
and body temperature responses of rats to recombinant human
interleukin-1 beta and a tripeptide interleukin-1 beta antagonist.
Physiol Behav 52:1155–1160
McLaughlin PJ, LuD,WinstonKM, Thakur G, Swezey LA,Makriyannis
A, Salamone JD (2005) Behavioral effects of the novel cannabinoid
full agonist AM 411. Pharmacol Biochem Behav 81:78–88
McLaughlin PJ, Thakur GA, Vemuri VK, McClure ED, Brown CM,
Winston KM, Wood JT, Makriyannis A, Salamone JD (2013) Be-
havioral effects of the novel potent cannabinoid CB1 agonist AM
4054. Pharmacol Biochem Behav 109:16–22
Merali Z, Brennan K, Brau P, Anisman H (2003) Dissociating anorexia
and anhedonis elicited by interleukin-1beta: anti-deprssant and gen-
der effects on responding for “free chow” and “earned” sucrose
intake. Psychopharmacology (Berl) 165(4):413–418
Miller AH (2009) Mechanisms of cytokine-induced behavioral changes:
psychoneuroimmunology at the translational interface. Brain Behav
Immunity 23:149–158
Mingote S, Font L, Farrar AM,Vontell R,Worden LT, Stopper CM, Port RG,
Sink KS, Bunce JG, Chrobak JJ, Salamone JD (2008a) Nucleus ac-
cumbens adenosine A2A receptors regulate exertion of effort by acting
on the ventral striatopallidal pathway. J Neurosci 28:9037–9046
Mingote S, Pereira M, Farrar AM,McLaughlin PJ, Salamone JD (2008b)
Systemic administration of the adenosineA(2A) agonist CGS 21680
induces sedation at doses that suppress lever pressing and food
intake. Pharmacol Biochem Behav 89:345–351
Minor TR, Huang Q, Foley EA (2003) Cytokine-purine interactions in
behavioral depression in rats. Integr Physiol Behav Sci 38:189–202
Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J,
Müller CE, Salamone JD (2009) The adenosine A2A antagonist
MSX-3 reverses the effects of the dopamine antagonist haloperidol
on effort-related decision making in a T-maze cost/benefit proce-
dure. Psychopharmacology (Berl) 204(1):103–112
Mouihate A, Chen X, Pittman QJ (1998) Interleukin-1beta fever in rats:
gender difference and estrous cycle influence. Am J Physiol 275(5
Pt 2):R1450–R1454
Nunes EJ, Randall PA, Santerre JL, Given AB, Sager TN, Correa M,
Salamone JD (2010) Differential effects of selective adenosine
antagonists on the effort-related impairments induced by dopamine
D1 and D2 antagonism. Neuroscience 170:268–280
Nunes EJ, Randall PA, Podurgiel S, Correa M, Salamone JD (2013)
Nucleus accumbens neurotransmission and effort-related choice
behavior in food motivation: effects of drugs acting on dopamine,
adenosine, and muscarinic acetylcholine receptors. Neurosci
Biobehav Rev, http://dx.doi.org/10.1016/j.neubiorev.2013.04.002
O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J,
Castanon N, Kelley KW, Dantzer R (2009) Interferon-gamma and
tumor necrosis factor-alpha mediate the upregulation of indoleamine
2,3-dioxygenase and the induction of depressive-like behavior in
mice in response to bacillus Calmette–Guerin. J Neurosci 29:4200–
4209
Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Muller CE,
Salamone JD, Correa M (2012) Adensoine A2A receptor antago-
nism and genetic deletion attenuate the effects of dopamine D2
antagonism on effort-related decision making in mice. Neurophar-
macology 62(5–6):2068–2077
Raedler TJ (2011) Inflammatory mechanisms in major depressive disor-
der. Curr Opin Psychiatry 24(6):519–525
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues:
inflammation and the pathogenesis of depression. Trends Immunol
27:24–31
Randall PA, PardoM, Nunes EJ, López Cruz L, Vemuri VK,Makriyannis
A, Baqi Y, Mϋller CE, Correa M, Salamone JD (2012) Dopaminer-
gic modulation of effort-related choice behavior as assessed by a
progressive ratio chow feeding choice task: pharmacological studies
and the role of individual differences. PLoS One 7(10):e47934
Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J (1998)
Immunohistochemical localization of adenosine A2A receptors in
the rat central nervous system. J Comp Neurol 401:163–186
Salamone JD, Correa M (2012) The mysterious motivational functions of
mesolimbic dopamine. Neuron 76(3):470–485
Salamone JD, Steinpreis RE,McCullough LD, Smith P, Grebel D,Mahan
K (1991) Haloperidol and nucleus accumbens (DA) depletion sup-
press lever pressing for food but increase free food consumption in a
novel food choice procedure. Psychopharmacology (Berl) 104:515–
521
Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of
nucleus accumbens dopamine: empirical and conceptual problems
with the anhedonia hypothesis. Neurosci Biobehav Rev 21:341–359
Salamone JD, Wisniecki A, Carlson BB, Correa M (2001) Nucleus
accumbens dopamine depletions make animals highly sensitive to
high fixed ration requirements but do not impair primary food
reinforcement. Neuroscience 105(4):863–870
Salamone JD, Arizzi MN, Sandoval MD, Cervone KM, Aberman JE
(2002) (DA) antagonists alter response allocation but do not sup-
press appetite for food in rats: contrast between the effects of SKF
83566, raclopride, and fenfluramine on a concurrent choice task.
Psychopharmacology (Berl) 160:371–380
Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM (2006)
Nucleus Accumbens (DA) and the forebrain circuitry involved in
behavioral activation and effort-related decision making: implica-
tions for understanding anergia and psychomotor slowing in depres-
sion. Curr Psychiat Rev 2:267–280
Salamone JD, Correa M, Farrar A, Mingote SM (2007) Effort-related
functions of nucleus accumbens dopamine and associated forebrain
circuits. Psychopharmacology (Berl) 191:461–482
Salamone JD, Farrar AM, Font L, Patel V, Schlar DE, Nunes EJ, Collins
LE, Sager TN (2009) Differential actions of adenosine A1 and A2A
antagonists on the effort-related effects of (DA) D2 antagonism.
Behav Brain Res 201:216–222
Salamone JD, Correa M, Nunes EJ, Randall PA, Pardo M (2012) The
behavioral pharmacology of effort-related choice behavior: dopa-
mine, adenosine, and beyond. J Exp Anal Behav 97(1):125–146
Santerre JL, Nunes EJ, Randall PA, Baqi Y, Müller CE, Salamone JD
(2012) Behavioral studies with the novel adenosine A2A antagonist
MSX-4: reversal of the effects of (DA) D2 antagonism. Pharamcol
Biochem Behav 102(4):477–487
Segovia KN, Correa M, Salamone JD (2011) Slow phasic changes in
nucleus accumbens dopamine release during fixed ratio acquisition:
a microdialysis study. Neuroscience 196:178–188
Segovia KN, Correa M, Lennington JB, Conover JC, Salamone JD
(2012) Changes in nucleus accumbens and neostriatal c-Fos and
DARPP-32 immunoreactivity during different stages of food-
reinforced instrumental training. Eur J Neurosci 35(8):1354–1367
Shuto H, Kataoka Y, Korikawa T, Fujihara N, Oishi R (1997) Repeated
interferon-alpha administration inhibits dopaminergic neural activity
in the mouse brain. Brain Res 747(2): 348–351
Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008)
Cannabinoid CB1 antagonists and dopamine antagonists produce
different effects on a task involving response allocation and effort-
related choice in food-seeking behavior. Psychopharmacology
(Berl) 196(4):565–574
Psychopharmacology (2014) 231:727–736 735
Song C, Li X, Kang Z, Kadotomi Y (2007) Omega-3 fatty acid ethyl-
eicosapentaenoate attenuates IL-1beta-induced changes in dopa-
mine and metabolites in the shell of the nucleus accumbens: in-
volved with PLA2 activity and corticosterone secretion.
Neuropsychopharmacology 32(2):736–744
Song C, Manku MS, Horrobin DF (2008) Long-chain polyunsaturated
fatty acids modulate interleukin-1beta-induced changes in behavior,
monoaminergic neurotransmitters, and brain inflammation in rats. J
Nutr 138(5):954–963
Taylor AN, Tio DL, Heng NS, Yirmiya R (2002) Alcohol consumption
attenuates febrile responses to lipopolysaccharide and interleukin-1
beta in male rats. Alcohol Clin Exp Res 26:44–52
Treadway MT, Bossaller NA, Shelton RC, Zald DH (2012) Effort-based
decision-making in major depressive disorder: a translational model
of motivational anhedonia. J Abnorm Psychol 121(3):553–558
Walton ME, Bannerman DM, Alterescu K, Rushworth MFS (2003)
Functional specialization within medial frontal cortex of the anterior
cingulate for evaluating effort-related decisions. J Neurosci 23:
6475–6479
Wardle MC, Treadway MT, Mayo LM, Zald DH, de Wit H (2011)
Amping up effort: effects of d-amphetamine on human effort-
based decision-making. J Neurosci 31(46):16597–16602
Worden LT, ShahriariM, Farrar AM, SinkKS, Hockemeyer J,Müller CE,
Salamone JD (2009) The adenosine A2A antagonist MSX-3 re-
verses the effort-related effects of dopamine blockade: differential
interaction with D1 and D2 family antagonists. Psychopharmacolo-
gy (Berl) 203(3):489–499
Wu TH, Lin CH (2008) IL-6 mediated alterations on immobile behavior
of rats in the forced swim test via ERK1/2 activation in specific brain
regions. Behav Brain Res 193:183–191
736 Psychopharmacology (2014) 231:727–736
